- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-5076
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
PARP inhibitors in the treatment of ovarian cancer ; day:13 ; month:3 ; year:2020 ; pages:1-4
Magazine of European Medical Oncology ; (13.3.2020), 1-4
- Creator
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12254-020-00585-1
- URN
-
urn:nbn:de:101:1-2020053100581162327694
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zeimet, Alain G.
- Wieser, Verena
- Knoll, Katharina
- Reimer, Daniel
- Marth, Christian
- SpringerLink (Online service)
Other Objects (12)
New treatment option for ovarian cancer: PARP inhibitors
PARP Inhibitors in Ovarian Cancer: A Review
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer
Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer
Efficacy of PARP Inhibitors in the Treatment of Ovarian Cancer: A Literature-Based Review
KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer
KLF5 Promotes Tumor Progression and Parp Inhibitor Resistance in Ovarian Cancer
PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives
Characterization of PARP inhibitor resistance in patient-derived ovarian cancer cell lines
CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options
New treatment option for ovarian cancer: PARP inhibitors
PARP Inhibitors in Ovarian Cancer: A Review
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer
Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer
Efficacy of PARP Inhibitors in the Treatment of Ovarian Cancer: A Literature-Based Review
KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer
KLF5 Promotes Tumor Progression and Parp Inhibitor Resistance in Ovarian Cancer
PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives
Characterization of PARP inhibitor resistance in patient-derived ovarian cancer cell lines
CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options
New treatment option for ovarian cancer: PARP inhibitors
PARP Inhibitors in Ovarian Cancer: A Review
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer
Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer
Efficacy of PARP Inhibitors in the Treatment of Ovarian Cancer: A Literature-Based Review
KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer
KLF5 Promotes Tumor Progression and Parp Inhibitor Resistance in Ovarian Cancer
PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives
Characterization of PARP inhibitor resistance in patient-derived ovarian cancer cell lines
CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer